United States Healthcare Equipment & Supplies

Heartflow Inc (HTFL)

Track

Over the past 90 days, Heartflow Inc. insiders have executed 12 transactions, all of which were sales totaling approximately $7.57 million. Key executives, including CEO John Farquhar and CMO Rogers Campbell, have consistently utilized planned sale programs. These transactions follow the company's May 2026 earnings report, amid a 12.8% decline in stock price.
Ticker: HTFL Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Heartflow Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Planned sale 15 Jul 2026
Value US$520,933.76 | Price 238.85 | Shares 83,140 (+10.4%)
Proposed sale 15 Jul 2026
Value US$4,449,414.14 | Price 380.01 | Shares 56,005
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-07-17 2026-07-15 PlS Planned sale
Rogers Campbell

Chief Medical Officer

Officer
83,140 +10.4%
238.85
US$520,934 		83,140 +10.4% 238.85 US$520,934
2026-07-15 2026-07-15 PrS Proposed sale
Rogers Campbell

Officer

Officer
56,005
380.01
US$4,449,414 		56,005 380.01 US$4,449,414
2026-07-13 2026-07-10 PlS Planned sale
Farquhar John C.M.

Chief Executive Officer

Executive Director
31,679 +35.1%
15.69
US$905,625 		31,679 +35.1% 15.69 US$905,625
2026-07-10 2026-07-10 PrS Proposed sale
Farquhar John C.M.

Officer; Director

Executive Director
22,562
27.75
US$626,096 		22,562 27.75 US$626,096
2026-06-26 2026-06-24 PlS Planned sale
Farquhar John C.M.

Chief Executive Officer

Executive Director
38,900 -7.8%
35.00
US$1,361,500 		38,900 -7.8% 35.00 US$1,361,500
2026-06-24 2026-06-24 PrS Proposed sale
Farquhar John C.M.

Officer; Director

Executive Director
38,900
35.00
US$1,361,500 		38,900 35.00 US$1,361,500
2026-06-12 2026-06-10 PlS Planned sale
Farquhar John C.M.

Chief Executive Officer

Executive Director
22,562 -4.3%
28.50
US$643,017 		22,562 -4.3% 28.50 US$643,017
2026-06-10 2026-06-10 PrS Proposed sale
Farquhar John C.M.

Officer; Director

Executive Director
22,562
28.50
US$643,017 		22,562 28.50 US$643,017
2026-05-20 2026-05-18 PlS Planned sale
Rogers Campbell

Chief Medical Officer

Officer
9,219 -10.5%
28.34
US$261,266 		9,219 -10.5% 28.34 US$261,266
2026-05-18 2026-05-18 PrS Proposed sale
Rogers Campbell

Officer

Officer
9,219
28.34
US$261,266 		9,219 28.34 US$261,266
2026-05-13 2026-05-11 PlS Planned sale
Farquhar John C.M.

Chief Executive Officer

Executive Director
22,562 -4.2%
29.12
US$657,005 		22,562 -4.2% 29.12 US$657,005
2026-05-11 2026-05-11 PrS Proposed sale
Farquhar John C.M.

Officer; Director

Executive Director
22,562
29.12
US$657,005 		22,562 29.12 US$657,005
2026-04-30 2026-04-30 S Sale
2.9
Bain Capital Life Sciences Investors, LLC
Large shareholder
56,224 -0.7%
30.05
US$1,689,531 		56,224 -0.7% 30.05 US$1,689,531
2026-04-30 2026-04-30 S Sale
2.9
Bain Capital Life Sciences Investors, LLC
Large shareholder
892,533 -9.5%
29.18
US$26,044,113 		892,533 -9.5% 29.18 US$26,044,113
2026-04-30 2026-04-29 S Sale
2.9
Bain Capital Life Sciences Investors, LLC
Large shareholder
797,133 -7.8%
29.37
US$23,411,796 		797,133 -7.8% 29.37 US$23,411,796
2026-04-30 2026-04-28 S Sale
2.9
Bain Capital Life Sciences Investors, LLC
Large shareholder
254,110 -2.4%
30.51
US$7,752,896 		254,110 -2.4% 30.51 US$7,752,896
2026-04-14 2026-04-10 PlS Planned sale
Farquhar John C.M.

Chief Executive Officer

Executive Director
22,562 -3.9%
26.72
US$602,857 		22,562 -3.9% 26.72 US$602,857
2026-04-10 2026-04-10 PrS Proposed sale
Farquhar John C.M.

Officer; Director

Executive Director
22,562
26.72
US$602,857 		22,562 26.72 US$602,857
2026-04-03 2026-04-01 PlS Planned sale
Rogers Campbell

Chief Medical Officer

Officer
64,533 -44.3%
24.64
US$1,590,093 		64,533 -44.3% 24.64 US$1,590,093
2026-04-01 2026-04-01 PrS Proposed sale
Rogers Campbell

Officer

Officer
64,533
24.64
US$1,589,935 		64,533 24.64 US$1,589,935
2026-03-23 2026-03-19 PlS Planned sale
Rogers Campbell

Chief Medical Officer

Officer
64,533 -45.1%
25.69
US$1,658,033 		64,533 -45.1% 25.69 US$1,658,033
2026-03-19 2026-03-19 PrS Proposed sale
Rogers Campbell

Officer

Officer
64,533
25.69
US$1,658,030 		64,533 25.69 US$1,658,030
2026-03-20 2026-03-18 PlS Planned sale
Farquhar John C.M.

Chief Executive Officer

Executive Director
9,725 -1.7%
25.00
US$243,125 		9,725 -1.7% 25.00 US$243,125
2026-03-18 2026-03-18 PrS Proposed sale
Farquhar John C.M.

Officer; Director

Executive Director
9,725
25.00
US$243,125 		9,725 25.00 US$243,125
2026-03-12 2026-03-10 PlS Planned sale
Farquhar John C.M.

Chief Executive Officer

Executive Director
12,837 -2.2%
22.66
US$290,886 		12,837 -2.2% 22.66 US$290,886
2026-03-10 2026-03-10 PrS Proposed sale
Farquhar John C.M.

Officer; Director

Executive Director
12,837
22.66
US$290,886 		12,837 22.66 US$290,886
2026-03-06 2026-03-05 PlS Planned sale
3.2
Cullivan Julie A
Non-Executive Director
9,122 -25.1%
25.00
US$228,050 		9,122 -25.1% 25.00 US$228,050
2026-03-05 2026-03-05 PrS Proposed sale
3.2
Cullivan Julie A

Director

Non-Executive Director
9,122
25.00
US$228,050 		9,122 25.00 US$228,050
2026-02-17 2026-02-12 PlS Planned sale
Rogers Campbell

Chief Medical Officer

Officer
65,153 -46.1%
24.49
US$1,595,486 		65,153 -46.1% 24.49 US$1,595,486
2026-02-12 2026-02-12 PrS Proposed sale
Rogers Campbell

Officer

Officer
65,153
24.49
US$1,595,485 		65,153 24.49 US$1,595,485
2026-02-10 2026-02-10 PlS Planned sale
Farquhar John C.M.

Chief Executive Officer

Executive Director
22,562 -3.7%
27.46
US$619,553 		22,562 -3.7% 27.46 US$619,553
2026-02-10 2026-02-10 PrS Proposed sale
Farquhar John C.M.

Officer; Director

Executive Director
22,562
27.46
US$619,557 		22,562 27.46 US$619,557
2026-02-12 2026-02-05 PrS Proposed sale
3.2
Cullivan Julie A

Director

Non-Executive Director
8,000
27.32
US$218,560 		8,000 27.32 US$218,560
2026-02-06 2026-02-05 PlS Planned sale
3.2
Cullivan Julie A
Non-Executive Director
8,000 -18.0%
27.32
US$218,560 		8,000 -18.0% 27.32 US$218,560
2026-02-05 2026-02-05 PrS Proposed sale
3.2
Cullivan Julie A

Director

Non-Executive Director
8,000
27.32
US$218,560 		8,000 27.32 US$218,560
2026-02-06 2026-02-04 S Sale
2.9
Bain Capital Life Sciences Investors, LLC
Large shareholder
2,000,000 -16.1%
28.05
US$56,100,000 		2,000,000 -16.1% 28.05 US$56,100,000
2025-12-17 2025-12-16 B Purchase
2.3
Lightcap Jeffrey C
Non-Executive Director
40,000 +inf%
26.34
US$1,053,680 		40,000 +inf% 26.34 US$1,053,680
Explore more

More insider trading research around Heartflow Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Healthcare Services companies with insider activity
More Healthcare Equipment & Supplies companies with insider activity
Insider trading in North America